MMP9 and neoplasm: S-III tumours exhibit more aggressive characteristics including the upregulation of proteins associated with a poor prognosis (such as TGFβ1, KRT19 and MMP9) and the activation of tumour-promotion pathways (such as TGFβ, HIF1, integrin and Rho GTPases pathways).